From Mesenchymal Stromal/Stem Cells to Insulin-Producing Cells: Immunological Considerations

Mesenchymal stem cell (MSC)-based therapy for type 1 diabetes mellitus (T1DM) has been the subject matter of many studies over the past few decades. The wide availability, negligible teratogenic risks and differentiation potential of MSCs promise a therapeutic alternative to traditional exogenous in...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Front Immunol
Päätekijät: Refaie, Ayman F., Elbassiouny, Batoul L., Kloc, Malgorzata, Sabek, Omaima M., Khater, Sherry M., Ismail, Amani M., Mohamed, Rania H., Ghoneim, Mohamed A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Frontiers Media S.A. 2021
Aiheet:
Immunology
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8262452/
https://ncbi.nlm.nih.gov/pubmed/34248981
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2021.690623
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia